Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Status:
Terminated
Trial end date:
2012-02-14
Target enrollment:
Participant gender:
Summary
Background:
- Tumor infiltrating lymphocytes (TIL) are white blood cells that have been taken from tumor
tissue. The cells are modified to help them kill tumor cells, then given back to the person
with cancer. By giving these cells to patients, researchers hope to improve the current
treatments available for patients with melanoma that has not responded to standard therapies.
The TIL will be given after treatments that will suppress the immune system. This makes it
easier for the TIL to attack the cancer cells. The TIL will also be given with aldesleukin
(IL-2), which is designed to help keep the TIL cells alive in the body.
Objectives:
- To study the safety and effectiveness of specially modified tumor infiltrating lymphocytes
to treat melanoma that has not responded to other treatments.
Eligibility:
- Individuals at least 18 years of age who have metastatic melanoma that has not responded to
other treatments.
Design:
- Participants will be screened with a physical exam and medical history. They will also
have blood tests and imaging studies.
- A piece of tumor will be collected and white blood cells will be separated to make the
TIL for the treatment.
- Participants will take drugs to suppress the immune system for 7 days before the start
of treatment.
- Participants will receive the TIL in a single dose. Then they will receive IL-2 every 8
hours for up to 15 doses. Participants will remain in the hospital for up to 2 weeks
after treatment. They will be monitored with frequent blood tests and other studies.
- After leaving the hospital, participants will have regular followup visits every 1 to 4
months for the first year. Then they will return for followup every 3 to 4 months, as
directed by the study researchers.